Explore trends before investing – request a sample report today! The Non-NGS Predictive Cancer Diagnostics Market is ...

Adaptive Biotechnologies (ADPT) announced growing interventional use of its clonoSEQ test among the 90 abstracts featuring clonoSEQ data at the ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Treatment preferences between survival and quality of life and their association with clinical outcomes in older adults with advanced cancer. Rates of first NGS relative to the time of death (in pts ...

Oxford Gene Technology (OGT), The Molecular Genetics Company, has teamed up with clinical research experts in a new article available online, discussing the role of next generation sequencing (NGS) in ...

Next Generation Sequencing (NGS) Market Poised to Hit $42.25 Billion by 2033: Key Drivers Behind the Surge - Latest Study by Grand View Research, Inc.

NCI-MATCH next-generation sequencing assay for detecting genetic mutations in tumors is sensitive, specific, and reproducible, reports The Journal of Molecular Diagnostics One of the most promising ...

A 46-year-old man with advanced lung cancer recovered after doctors used Next Generation Sequencing to identify a rare ALK ...

“Emerging technologies leveraging ctDNA and NGS are increasing our ability to identify cancers in high-risk patients, which was previously beyond reach,” said Dr. Nathan Montgomery, Vice President of ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received ...

FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress ...